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Available online xxxxTreatment for type 1 Gaucher disease (GD1) decreases morbidity from hematological cytopenias,
hepatosplenomegaly and bone complications. Consequently, untreated symptomatic patients for study of late
outcomes are hard to ﬁnd. We identiﬁed 184 untreated GD1 patients (67.4% Ashkenazi; splenectomy 51.1%)
who died between 1950 and 2010. Here, we report conﬁrmed causes of death for these patients compared
with the overall US population. Median age of death 66 years (2–97 years); causes of death (COD) with a high
proportional mortality rate (PMR) included malignancies (PMR 1.57), suicide/drug overdose (PMR 3.86), liver
disease (PMR 4.76) and septicemia (PMR 9.22). PMRs for CNS/gastrointestinal bleeding, pulmonary hyperten-
sion, post-splenectomy complications and Parkinsonism were also increased. PMR for heart disease (0.33) was
signiﬁcantly decreased. Average age at deathwas normal for heart disease, septicemia, suicide, andmalignancies
but younger for liver disease and Parkinsonism. CODmore prevalent in splenectomy patients included liver dis-
ease, septicemia, pulmonary hypertension and GI bleeding.With timely diagnosis, improved risk assessment and
obsolescence of splenectomy, GD1-associated malignancies, liver disease, septicemia, pulmonary hypertension,
suicide and drug dependencymay decreasewith early institution of appropriate treatment. Our population of un-
treated patients is a valuable historical control for studies of the effect of GD1 treatment on prematuremortality.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Type 1 Gaucher disease (GD1) is caused by mutations in the gene
encoding lysosomal glucocerebrosidase (GBA1) with resultant life-
long accumulation of the enzyme substrate glucosylceramide predomi-
nantly although not exclusively within hepatic, splenic, pulmonary and
bonemarrowmacrophages [1]. Enzyme replacement therapy (ERT), in-
travenous infusion of recombinant glucocerebrosidase (imiglucerase,
velaglucerase alfa, taliglucerase alfa) has proven to be generally safe
and effective in decreasingmorbidity attributable to the heterogeneous
clinical manifestations of GD1: hematological cytopenias, symptomatic
hepatosplenomegaly, bone pain, osteonecrosis, and osteopenia [2]. Oral
substrate reduction therapy (SRT) by inhibition of glucosylceramide
synthase (miglustat and eliglustat tartrate) is also now approved and
prescribed for select GD1 patient populations [3]. Attention is now
being focused on longer term complications whose responsiveness to
conventional treatment is yet undetermined: atypical Parkinsonism
often complicated by dementia and an increased risk for malignancies,dation for Lysosomal Storage
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, Blood Cells Mol. Diseases (20particularly but not exclusively, myeloma and other plasma cell dyscra-
sias, other hematological and lymphoid malignancies and hepatocellu-
lar carcinoma [4–7].
Because of widespread use of ERT during the 25 years that it has
been available in Western countries [8] and the attrition of older medi-
cal records, a control group of phenotypically representative, untreated
symptomatic patients for study of these late outcome events is hard to
come by. Fortuitously, between years 1961–1997, one of us (REL) col-
lected basic clinical information on 395 US patients with GD1 [9]. We
determined through public records that between years 1950–2010,
217 have died, of whom, to our best knowledge, 184 never received
ERT or other deﬁnitive treatment for GD1. Here, we annotate and ana-
lyze conﬁrmed causes of death (COD) for the untreated GD1 patients
compared to COD reported for this time period in an age comparable
general Caucasian US population. A sub-analysis of deaths caused by
malignancies has been previously published [10].
2. Method
Following IRB approval, primary and secondary COD as recorded in
ofﬁcial death certiﬁcates were accessed from the National Death Index
(NDI) for available years 1979–2008. GD1 was included among the di-
agnoses on the death certiﬁcate in only 71/152 patients (46.7%). CODthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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formation given to REL and, where possible, conﬁrmed by death certif-
icates obtained from State Bureaus of Vital Records. To our knowledge,
no untreated patient has died subsequent to 2008. COD could not be de-
termined for 9 patients all of whom died prior to 1979. Information on
COD (1950–2008) for the general US white population is from US Na-
tional Vital Statistics Reports available on-line [11]. Proportionalmortal-
ity for each COD was determined at 5–8 years interval from 1950 to
2008 and mean values with 95% conﬁdence intervals were calculated.
The proportional mortality for each disease was compared to the
mean value in the reference population.
In order to determine whether patients with GD1 died at a younger
age than reference population patients with the same cause of death,
proportional mortality ratios (PMR) were calculated for each disease
by 10 year age intervals commencing at age 5 years.
The analysis included descriptive statistics, calculation of propor-
tional mortality ratios [12], Χ2 testing, and 2-tailed Fisher exact test cal-
culations based on absolute death numbers in the GD1 and general
population.
3. Results
Select demographics of the 184 patients who never received ERT or
other deﬁnitive treatment for GD1 were calculated and are displayed in
Table 1. The cohort includes 111/184 males (60.3%). Ethnicity in refer-
ence to Ashkenazi Jewish background was assessed at 124/184
(67.4%). The median age at death was 66 years (2–97 years) and the
median year of death was 1984 (1923–2008). The median age at GD1
diagnosis (N= 102) was 39 years (1–83 years). Symptomatic bone dis-
ease was present in 74/184 (40.2%), absent in 7 (3.8%) and undocu-
mented for 103 (60.0%) patients. Patients in whom a known
splenectomy had been performed (94/184) represented 51.1% of the
study population. The age at the time of the procedure was found for
88 of the 94 patients and the median age at splenectomy was 36 years
(1.3 years–78 years). The remaining patients either had intact spleens,
56/184 (30.4%) or their status was unknown 34/184 (18.5%).
Further demographic analysis is shown in Table 2. Patients were
sub-divided into 3 birth eras so as to reﬂect the substantial increase in
general life expectancy in the US population between 1885 and 1975
(a range encompassing the birth years of all of the study patients).
This time frame also encompasses the period of large scale emigration
of Jews from eastern and central Europe to the US and the expansionTable 1
Demographics of deceased, untreated GD1 study subjects with a date of death between 1950 a
Patients (N = 184) P
Age at death Years S
Mean (SD) 62.8 (19.7)
Median 66
Range 2–97
Mid-quartile range 51.8–77.0 S
5th–95th percentile 25.2–88.9
Year of death Mean (SD) 1983 (12.7)
Median 1984
Mid-quartile range 1975–1992
5th–95th percentile 1959–2003 A
Year of birth N (%)
1885–1914 80 (43.5)
1915–1944 81 (44.0)
1945–1975 23 (12.5)
Gender N (%) A
Male 111 (60.3)
Female 73 (39.7)
Ethnicity
N (%)
Ashkenazi Jewish 124 (67.4)
Other/Unknown 60 (32.6)
Please cite this article as: N.J. Weinreb, et al., Blood Cells Mol. Diseases (20of theUSAshkenazi Jewish population fromminiscule to approximately
6 million. For the 79 GD1 patients in our study who were born prior to
1914, nearly 80% were Ashkenazi Jews, a percentage that progressively
decreased in the two later birth eras. The median age at diagnosis was
60 (17–83) years and was substantially higher than that reported for
study patients born between the two World Wars (28, 3–68 years)
and those born after 1945 (4.5, 1–32 years). Fewer pre-1914 study sub-
jects underwent splenectomy compared with those born later and
where data is available, the median age at splenectomy was 59 years
compared with 37 and 7.5 years for the later eras. Symptomatic bone
disease also seemed somewhat less prevalent in subjects born prior to
1914 but data are not available for the majority of patients, regardless
of birth year. 95% of the study subjects born prior to 1914 lived longer
than the average 50 year US life expectancy for patients born between
1885 and 1914. The median age at death was 75 (42–97) years. On av-
erage, subjects born between 1914 and 1945 achieved the 60 year life
expectancy for that time but 25% (N = 21) died younger than
50 years of age. Among subjects born between 1945 and 1975 (N =
23), the median age at death was 29 (2–55) years and only 2 patients
lived to be older than 50 years. The average US life expectancy during
this time frame was 69.6 years.
Causes of death could not be determined for 9 patients all of whom
died prior to 1979. The different COD for the study population are com-
pared with the control US general population in Table 3. COD for which
the proportional mortality rate (PMR) was signiﬁcantly increased
(p b 0.01) in this untreated GD1 population included malignant neo-
plasms (PMR 1.57), suicide and drug overdose (PMR 3.86), chronic
liver disease and cirrhosis (PMR 4.76) and septicemia (PMR 9.22).
Other causes of death that were disproportionately represented in this
GD1 patient population included CNS and gastrointestinal bleeding,
post-splenectomy complications, pulmonary hypertension and/or ﬁ-
brosis, and Parkinsonism. Heart disease/atherosclerosis was the only
COD for which PMR was very signiﬁcantly decreased (0.33).
COD was further categorized by spleen status. The median age of
death for individuals who had undergone splenectomy (94/184) was
62.5 years. Themedian age of death for individualswith an intact spleen
(56/184) was72.5 years and for those with an unknown spleen status
(34/184) 68 years. Causes of death signiﬁcantlymore prevalent in surgi-
cally asplenic patients included chronic liver disease, pulmonary hyper-
tension/ﬁbrosis, post-splenectomy complications, GI bleeding and
otherwise unspeciﬁed complications attributed to Gaucher disease
(Fig. 1).nd 2008.
atients (N = 184)
ymptomatic bone disease N (%)
Present 74 (40.2)
Absent 7 (3.8)
Unknown 103 (60.0)
pleen status
N (%)
Splenectomy 94 (51.1)
Intact 56 (30.4)
Unknown 34 (18.5)
ge at splenectomy N = 88 Years
Mean (SD) 36.1 (21.6)
Median 36
Range 1.3–78
Mid-quartile range 13.8–54
5th–95th percentile 4–65.7
ge at diagnosis N = 102 Years
Mean (SD) 38.8 (23.4)
Median 39
Range 1–83
Mid-quartile range 21–60
5th–95th percentile 3–75
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Table 2
Demographics, age at death, age of diagnosis, splenectomy status and presence of symp-
tomatic bone disease in study subjects sub-divided by year of birth.
Year of birth 1885–1914 1915–1944 1945–1975
Average US life expectancy at birth 50.0 (1.3) 59.7 (3.6) 69.6 (1.4)
Age at death (y) N = 79 N = 82 N = 23
Mean (SD) 74.0 (12.2) 62.0 (13.8) 27.2 (14.4)
Median 75 64.5 29
Range 42–97 30–89 2–55
Mid-quartile range 65–82.5 51–72.8 18–36
5th–95th percentile 53–93 38–81 4.3–51.2
Gender
Male N (%) 44 (55.7) 53 (64.6) 14 (60.9)
Female N (%) 35 (44.3) 29 (35.4) 9 (39.1)
Ethnicity
Ashkenazi 63 (79.7) 51 (62.2) 10 (43.5)
Other/unknown 16 (20.3) 31 (37.8) 13 (56.5)
Age at diagnosis N = 44 N = 42 N = 16
Mean (SD) 56.1 (16.9) 31.4 (17.8) 10.3 (10.3)
Median 60 28 4.5
Range 17–83 3.5–68 1–32
Mid-quartile range 44.5–70.3 18.5–43.8 3.0–15.8
5th–95th percentile 28.2–76.0 5.0–62.8 1.8–28.3
Spleen status N (%) N (%) N (%)
Splenectomy 27 (34.2) 50 (61.0) 17 (73.9)
Intact 34 (43.0) 17 (20.7) 5 (21.7)
Unknown 18 (22.8) 15 (18.3) 1 (4.4)
Age at Splenectomy (y) N = 25 N = 47 N = 16
Mean (SD) 53.7 (14.5) 35.5 (18.6) 10.4 (8.9)
Median 59 37 7.5
Range 23–78 3–66 1.25–34
Mid-quartile range 46–62 22.8–50.3 4.0–13.3
5th–95th percentile 32–75 5.3–64.1 1.8–27.3
Symptomatic bone
disease
All SpleneX All SpleneX All SpleneX
Present N (%) 28
(35.0)
9 (33.3) 35
(43.2)
24
(48.0)
11
(47.8)
9 (52.9)
Absent N (%) 3 (3.8) 1 (3.7) 3 (3.7) 1 (2.0) 1 (4.4) 0
Unknown N (%) 49
(61.2)
17
(63.0)
43
(53.1)
25
(50.0)
11
(47.8)
8 (47.1)
3N.J. Weinreb et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxAs previously reported [10], among the 57 patients who died of ma-
lignancies the proportional mortality rates were signiﬁcantly increased
(p b 0.01) for myeloma (9.66), kidney CA (4.63), liver CA (4.36), NHL
(4.13), and all leukemia (3.19). To our surprise, the PMR for lung CA
was 0.32 (p= 0.002). There was only 1 death from breast CA and single
deaths from brain and CNS CA, larynx CA, oral cavity/pharynx CA and
melanoma. No GD1 patients were found to have died from esophageal,
cervical, ovarian, or stomach cancers. PMR for colorectal, pancreatic and
prostate CA were not divergent from expected values. The median age
of death from cancer for individuals who had undergone splenectomy
(94/184) was 62.5 years compared to 72.5 years for individuals with
an intact spleen (56/184). For those with an unknown spleen statusTable 3
All causes of death for untreated GD1 study subjects with a date of death between 1950 and 2
Cause of death GD PTS Mean % all deaths 95% limits
Heart disease and atherosclerosis 20 34.9 31.5–38.3
Malignant neoplasms 57 20.7 19.0–22.4
Cerebrovascular disease and stroke 7 8.3 7.0–9.6
Accidents 1 5.0 4.6–5.4
COPD and related conditions 4 3.2 2.1–4.3
Pneumonia and inﬂuenza 5 3.0 2.7–3.3
Diabetes mellitus 2 2.2 1.9–2.5
Suicide and drug overdose 9 1.3 1.2–1.4
Chronic liver disease and cirrhosis 11 1.3 1.1–1.5
Chronic kidney disease 4 1.1 0.8–1.4
Septicemia 14 0.9 0.6–1.2
Alzheimers and dementia 3 1.8 0.2–2.0
All other causes 38 17.4 16.0–18.8
Please cite this article as: N.J. Weinreb, et al., Blood Cells Mol. Diseases (20(34/184) the median age was 69.5 years. Spleen status appeared irrele-
vant to prevalence of CA deaths includingmyeloma butwas relevant for
hepatocellular CA (splenectomy) and chronic lymphocytic leukemia
(intact spleen) [10].
Compared to the control US population, the age distribution of
deaths as a percentage of all deaths attributed to a speciﬁc cause of
death appeared to be similar for heart disease and cancer diagnoses as
a whole (Fig. 2A, B). Due to small numbers in our study population for
each age point, statistical analysis was not attempted. Nevertheless,
early deaths due to septicemia, chronic liver disease, suicide and possi-
bly Parkinsonism appeared to be more common in the untreated GD1
subjects than in the control population (Fig. 2C–F).
4. Discussion and conclusions
Current ERTs and SRTs for patients with Gaucher disease were ap-
proved on the basis of small, usually short-term, randomized and non-
randomized clinical trials whose endpoints were largely restricted to
surrogate markers such as quantitative changes in hemoglobin concen-
tration, platelet counts, biochemical markers, spleen and liver volumes,
bone marrow burden scores and bone mineral density [2]. Longer term
extension and post-marketing registry studies are also largely focused
on these parameters [13–19]. With the exception of bone pain, studies
focusing on patient reported outcomes are sparse and largely restricted
to health-related quality of life measured with generic instruments, fa-
tigue, and pregnancy associated events [20–25]. Although the clinical
efﬁcacy (if not necessarily the cost effectiveness) of GD-speciﬁc treat-
ments is generally accepted and further supported byMarkovmodeling
studies [26,27], evidence that such therapy reduces premature mortali-
ty caused by possibly preventable GD complications such as splenecto-
my-associated morbidity, clinical bone events, chronic liver disease,
pulmonary hypertension, Parkinsonism and malignancies would be
compelling. Unfortunately, despite enrollment of several thousand
GD1 patients in national and international GD registries and many pa-
tient-years of follow up, there are yet no reported annotative studies
of causes of death that compare untreated with treated patients.
With the advent and lengthy availability of effective GD-speciﬁc
treatments in all developed countries, identifying parallel cohorts of
phenotypically matched treated and untreated deceased patients for
cause of death analyses seems nigh impossible. Although fraught with
methodologic difﬁculties caused by changes over decades in societal
health practices and disease prevalences as well as ascertainment bias,
there seems to be no alternative to an historical control comprised of
GD1 patients who died before ERT became available. Our study popula-
tion of 184 untreated people with GD1 who died between 1950 and
2008 is the largest number (untreated or treated) in whom the causes
of death have been annotated and analyzed. Based on ICD-10 codes
and death certiﬁcates from 11 US states, Barczykowski et al. calculated
an annual mortality rate for GD1 patients of 0.073 per million [28].008.
GD PTS (%) PMR P value Fisher exact 2-tailed O/E CHI test
1.00
11.4 0.33 p b 0.0001 0.00000 0.33 0.0000
32.6 1.57 p = 0.0002 0.00017 1.57 0.0001
4.0 0.48 p = 0.0271 0.02710 0.48 0.0397
0.6 0.12 p = 0.003 0.00258 0.12 0.0074
2.3 0.72 NS 0.82754 0.72 0.4920
2.9 0.96 NS 0.65444 0.96 0.9291
1.1 0.51 NS 0.44736 0.51 0.3306
5.1 3.86 p = 0.00014 0.00014 3.86 0.0000
6.3 4.76 p b 0.0001 0.00003 4.76 0.0000
2.3 2.16 NS 0.11560 2.16 0.0993
8.0 9.22 p b 0.0001 0.00000 9.22 0.0000
1.7 0.93 NS 1.00000 0.93 0.9102
21.7 1.25 NS 0.13449 1.25 0.1294
16), http://dx.doi.org/10.1016/j.bcmd.2016.10.002
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Fig. 1. Causes of death in the Pittsburgh Registry untreated patient population grouped by spleen status. A. Patients post-splenectomy, with intact spleens, and with splenectomy status
unknown. B. Patients either post-splenectomy orwith intact spleens. Patients inwhom spleen status is unknownwere assigned to one of the two groups as described in the footnote to the
ﬁgure. *Imputed calculation. Among patients with known spleen status, the ratio of splenectomy patients to those with intact spleens is approximately 3:1. Patients with unknown
splenectomy status were ranked by the age at death. Because the oldest patients at time of death were least likely to have had a splenectomy, the top quartile of the “unknown”
patients (N = 11) were assigned to the intact spleen cohort and the others (N= 31) to the splenectomy cohort.
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cluded among the causes of death on b50% of the death certiﬁcates
we reviewed.) Assuming an average US population of 225 million be-
tween 1950 and 2010, 952 individuals with GD1 should have died in
that interval. Therefore, our study of 184 patients should theoretically
represent 10–20% of all US deaths from GD1 from 1950 to 2010.
Our study conﬁrms the common impression that, prior to 1991 (the
pre-treatment era), GI and CNS bleeding, cirrhosis/portal hypertension,
pulmonary hypertension, septicemia and surgical complications associ-
atedwith splenectomy often led to premature death. These causes were
predominant among our patients who died prior to age 55 years. Our
ﬁnding of a nearly 4-fold greater than expected occurrence of deaths
due to suicide or drug overdose in untreated GD1 patients (Table 2) is
novel.
There is little other information about GD mortality due to these
causes in the pre-ERT/SRT era. In a 1948 case study of 9 German and
Dutch GD1 patients (one non-Jewish), Groen and Garber reported 7
deaths [29]: a 48 year old post-splenectomy patient with pulmonary
hypertension and cor pulmonale; a 33 year old with immediate post-
splenectomy bleeding; a 30 year old on a long term, markedly protein
restricted vegan-type diet with wasting, edema and possible chronic
liver disease. The other 4 patients died in German concentration
camps, a cause of death that hopefully will never be replicated. One sur-
viving patient had a successfully resected pancreatic islet cell tumor.
The other survived a concentration camp but developed pulmonary tu-
berculosis. The authors also presciently commented about the frequen-
cy of cholelithiasis, the full spectrum of classical but variable GD bone
complications, the marked phenotypic heterogeneity associated withPlease cite this article as: N.J. Weinreb, et al., Blood Cells Mol. Diseases (20GD1, the correlation between early age of onset and disease severity,
and the need to avoid splenectomy when possible.
In 1954, Medoff and Bayrd described 29 GD1Mayo Clinic patients of
whom 8 were lost to follow up [30]. 12 of 21 patients appeared to have
died but the COD was detailed only in two patients both of whom died
shortly after splenectomy. Four other splenectomy patients died at age
4 years (1 year post-op), 40 years (14 years post-op), 42 years
(6 years post-op) and 48 years (21 years post-op) for unspeciﬁed rea-
sons. Six of 15 splenectomy patients were known to be alive 11–
20 years post-operatively comparedwith 3 of 14with intact spleens. Be-
cause patients had sustained hematologic improvement after splenec-
tomy, the authors concluded that there are no contraindications to
splenectomy other than technical considerations. Despite the report of
Groen et al. [29], prior to 1991, there are only 3 Pub Med case reports
of GD and pulmonary hypertension [31–33]. This is surprising consider-
ing the number of splenectomies that were performed in the pre-ERT
era. However, among 48GDpatientswhounderwent total (75%) or par-
tial (25%) splenectomy at Mount Sinai Hospital NY between 1963 and
1989, there was one intraoperative death due to massive bleeding,
and, over a mean follow up period of 5–6 years, 8 subsequent deaths
due to hematologic malignancies (3), sepsis (1), progressive Gaucher
disease (1) and unrelated to GD (3). There were no deaths attributable
either to pulmonary hypertension or chronic liver disease [34]. Autopsy
ﬁndings on a GD1 patient with cirrhosis and ascites were reported in
1955 [35]. A fatal case of GD “masquerading” for several years as cirrho-
sis was published in 1964, and a death in what was described as the
“seventh known case” of a pediatric GD patient with portal hyperten-
sion and hepatic ﬁbrosis was reported in 1975 [36,37]. Among 2116), http://dx.doi.org/10.1016/j.bcmd.2016.10.002
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Fig. 2.Distribution of ages at death in the Pittsburgh Registry population comparedwith theUS general population for six causes of death. A. Heart disease. B.Malignancies. C. Liver disease.
D. Parkinsons disease. E. Septicemia and infection. F. Suicide and drug overdose.
5N.J. Weinreb et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxpatients with GD1 whowere investigated for liver disease in 1981, only
3 were found to have cirrhosis and portal hypertension. One patient,
who also had severe myelophthisic anemia died [38].
There are, as yet, few data aboutmortality and causes of death in pa-
tients inwhom ERT or SRTwas initiated after 1991. The French Gaucher
Registry described 378GD1patients of whom298 (78.8%)were on ERT/
SRT and 27.5%were post-splenectomy [39]. 20patients died at amedian
age of 64.5 years (38 years–83 years; N= 13). 15 patients were receiv-
ing ERT/SRT. The cause of death was unknown in 9 patients. Four pa-
tients died of malignancy (lymphoma-2; myeloma-1; osteosarcoma-
1). Two patients suffered cardiac deaths (MI), 2 died with pulmonary
hypertension and 3 with Parkinson disease. Among 370 GD1 patients
enrolled in the Spanish Gaucher Registry, 62 patients (17.4%) were
post-splenectomy and 84% were on GD treatment [40]. 28 patients
were reported to have died at a mean age of 60.1 years (33 years–
78 years). Themost common causes of death were malignancy (myelo-
ma-3; lymphoma-2; liver CA-1;melanoma-1; colon CA-1; gastric CA-1),
pulmonary hypertension (5), liver failure, Parkinson disease, andPlease cite this article as: N.J. Weinreb, et al., Blood Cells Mol. Diseases (20septicemia. Despite the lower splenectomy rates, the prevalent causes
of death in both studies are similar to those we found in untreated
patients.
The International Collaborative Gaucher Group (ICGG) Registry re-
ported causes of death for 63 of 102 deceased GD1 patients who were
enrolled between 1991 and 2006 [41]. 90% were treated with imigluce-
rase for amedian 5.4 years prior to their deaths. As shown in Table 4, the
median age at death in the ICGG population was 61 years and 25% died
before age 45 years. These results in treated patients are very similar to
what we found in our untreated patients as was the percentage of post-
splenectomy patients (48% and 51%). Therefore, it is not surprising that
as with the French and Spanish studies, there was little difference be-
tween the ICGG study and our pre-treatment study in the proportions
of patientswhose deathswere attributed to heart disease,malignancies,
liver disease, pulmonary hypertension and bleeding (Table 4). Deaths
due to infection and septicemia may be proportionately greater in our
population than in the ICCG cohort because of the advent of better anti-
biotics and infection control in more recent times. In the ICCG study,16), http://dx.doi.org/10.1016/j.bcmd.2016.10.002
Table 4
Causes of death in patients with GD1 who were never treated with GD-speciﬁc therapy
(Pittsburgh Registry) compared with COD in ICCG Registry patients of whom 90% were
treated with ERT for a median 5.4 years.
Study population Pittsburgh Registry ICCG Registry
N = 184 N = 102
Median age at death
(25,75 percentile)
66 years
(52 years, 77) years
61 years
(44 years,
75 years)
% with splenectomy 51 48
N (% of
known COD)⁎
N (% of
known COD)⁎⁎
Known COD 175 (95.1) 63 (61.8)
Heart disease 20 (11.4) 9 (14.3)
Malignancy 57 (32.6) 17 (27.0)
Cerebrovascular 7 (4.0) 6 (9.5)
Parkinson disease 6 (3.4) 0
Other neurological 3 (1.7) 5 (7.9)
COPD and unspeciﬁed lung disease 5 (2.9) 2 (3.2)
Accidents 1 (0.6) 1 (1.6)
Suicide and overdose 9 (5.1) 0
Diabetes 2 (1.1) 0
Pulmonary hypertension 4 (2.3) 2 (3.2)
Liver disease 11 (6.3) 4 (6.3)
Infections and septicemia 19 (10.9) 4 (6.3)
Renal disease 4 (2.3) 1 (1.6)
Bleeding 11 (6.3) 3 (4.8)
All other causes 16 (9.1) 9 (15.9)
⁎ All other deaths from the following causes: post-splenectomy complications; Gaucher
disease, unspeciﬁed; aplastic anemia, HIV, gangrene, pulmonary embolism.
⁎⁎ All other deaths from the following causes: multiple organ failure, pulmonary edema,
pancytopenia, dehydration, and complications from bone marrow transplant or coronary
artery bypass surgery.
6 N.J. Weinreb et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxwith the large amount of missing COD data (38.2%), the absence of
deaths due to Parkinsonism may reﬂect underreporting or inclusion of
Parkinson death in the “other neurological” category. Although neither
suicide nor drug overdose were reported as causes of death in the
ICGG, French or Spanish studies, our current experience indicates that
analgesic drug abuse and depression continue to afﬂict even adequately
treated GD1 patients and should be recognized and addressed by
treating physicians.
In reality, we did not anticipate that a signiﬁcant change in causes of
death would emerge from a comparison of our ﬁndings in historical un-
treated GD1 patients with early, preliminary and incomplete results in
patients on ERT/SRT that commenced often many years after diagnosis
and onset of symptoms and was administered for a relatively short pe-
riod of time. Rather, we anticipate that with earlier diagnosis, improved
risk assessment and phase-out of splenectomy [26,42], plausibly avoid-
able causes of premature death observed in our study population
(chronic liver disease, GI bleeding, septicemia, PHT, suicide and drugde-
pendency) should be increasingly rare with timely institution of appro-
priate treatment.
As a reference control, our patient cohort has some signiﬁcant limita-
tions. Althoughwe estimate that our population of deceased, never treat-
ed patients includes 10–20% of all GD1 deaths experienced in the US
between 1950 and 2008, it is likely skewed towards deaths in older indi-
viduals and fails to include causes of death for patients born in the late
nineteenth and early twentieth centuries who died from GD complica-
tions at a young age (i.e. prior to 1950). It is also largely populated by
Ashkenazi Jewish patients many of whom may have had somewhat
less severe phenotypes and a different natural history than typically
seen in non-JewishGDpopulations. On the other hand, because the Pitts-
burgh Registry was a voluntary informational database, many of the en-
rolled patients may have been cherry picked by referring physicians,
with selection bias favoring only the most severely affected or “interest-
ing” patients and excluding patients with verymild phenotypes. It is also
possible that not all causes of death were included on death certiﬁcatesPlease cite this article as: N.J. Weinreb, et al., Blood Cells Mol. Diseases (20as highlighted by the fact that the diagnosis of Gaucher diseasewas omit-
ted on half the death certiﬁcates we examined.
Nevertheless, our study results, including those published previous-
ly [10], conﬁrm that as part of the natural history of type 1 Gaucher dis-
ease, adverse events including myeloma, B cell lymphoma, acute
myeloid leukemia, liver and kidney cancers, Parkinsonism, chronic
liver disease, infections and septicemia, suicide and drug abuse and
overdose lead to premature mortality and are important targets for
therapeutic intervention. The unexpectedly low occurrence we identi-
ﬁed of lung, breast and gynecological cancers as causes of death in
GD1 patients suggests that we should think about GD1 not only in
terms of cancer induction, but also as it may relate to tumor-speciﬁc
proclivities for metastatic disease. The relatively low occurrence of
death due to atherosclerotic cardiovascular disease and diabetes
mellitus in untreated patients is supportive of published investigations
of carbohydrate and lipid metabolism in patients with GD1 that merit
further observation of the effect of GD-speciﬁc therapies on these dis-
ease entities [43,44]. We conclude that our study population of untreat-
ed patients is a valid (possibly unique) control againstwhich to evaluate
the effect of GD1 treatment on mortality due to malignancy and other
later course events.
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